269. Pyogenic arthritis Clinical trials / Disease details
Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04274166 (ClinicalTrials.gov) | May 2021 | 12/2/2020 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: secukinumab 150 mg (2 injections per dose | Wake Forest University Health Sciences | Novartis | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States |